Multimodality Microendoscope for Metastatic Ovarian Cancer Detection & Treatment
Multimodality Microendoscope for Metastatic Ovarian Cancer Detection & Treatment
批准号:
7800294
负责人:
Conor Lee Evans
金额:
$2.57万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2010-09-01
关键词:
AbdomenAbdominal CavityAdriamycin PFSAnimal ModelBlood CirculationCancer DiagnosticsCancer EtiologyCardiologyCatalogingCatalogsCessation of lifeClinicalCollaborationsDetectionDevelopmentDevicesDiagnosisDiagnosticDisciplineDiseaseDistalDistant MetastasisDrug resistanceEarly DiagnosisEffectivenessElementsEndoscopyEnsureEnvironmentEpithelialEpithelial ovarian cancerFiberFluorescenceGastroenterologyGeneral HospitalsGoalsImageImageryImaging technologyIn SituIn VitroIndividualInvadedLifeLymphMalignant NeoplasmsMalignant neoplasm of ovaryMassachusettsMethodologyMethodsMicrometastasisMicroscopicModelingMonitorMorphologyNamesNeoplasm MetastasisNoduleOperative Surgical ProceduresOphthalmologyOptical Coherence TomographyOrganOvarian DiseasesPerformancePhotochemotherapyPhotosensitizing AgentsRadiationResearchResidual TumorsResolutionSamplingScanningScreening for Ovarian CancerSiteSpecificityStagingStructureSurvival RateSymptomsSystemTechniquesTechnologyTestingTherapeuticTimeTissuesTrainingTreatment EffectivenessTreatment ProtocolsWomanWorkbasebioimagingcancer therapychemotherapyclinical applicationcritical periodcytotoxicexperiencefightingimaging modalityimaging probeimprovedmedical specialtiesminimally invasivemolecular imagingmortalitymouse modelmultimodalitynovelovarian neoplasmpublic health relevancerapid detectionresearch studysuccesstechnological innovationtranslational approachtreatment programtumortumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Ovarian epithelial cancer is the fifth leading cause of cancer death among women in the US, and has the highest fatality-to-case ratio of all gynecological cancers. Ovarian cancer is especially dangerous due to its propensity to rapidly metastasize, as the disease invades tissues throughout the abdomen by exfoliating from the original tumor. 90% of all ovarian cancer fatalities arise from this occult metastatic disease, which often is composed of a multitude of micrometastases that are exceedingly difficult to detect. While white-light and fluorescence endoscopy have been used, their selectivity and sensitivity have been too limited to accurately detect the microscopic, deadly metastases without high false-positive and false-negative rates. Without the ability to detect this sub-clinical disease state, many women miss a critical period where alternative chemotherapy or radiation treatment might be lifesaving. It is the long-term goal of this project to improve the dismal survival rates (<30%) of ovarian cancer by building, testing, and deploying a sensitive new paradigm for micrometastases detection. In the first aim, this proposal combines the visualization of suspect tumors in situ by fluorescence with the structurally sensitive optical coherence tomography (OCT) imaging technology to provide a selective, sensitive, and fully quantitative microscopic imaging probe for ovarian cancer diagnostics. By utilizing the fluorescence detection for rapid examination and OCT for 3D structural imaging, this in situ probe will not only visualize a tumor, but also render its underlying tissue structure, size, and vasculature. This approach will be realized as a microendoscope composed of tens of thousands of individual image elements that are scanned proximally to ensure a small distal form factor for minimally invasive imaging. In the second specific aim, three-dimensional tumor models and ex vivo tissues will be used for extensive characterization and cataloging so that the multimodal contrast can be used for in situ diagnosis of occult metastatic disease in any tissue. These experiments will find immediate use in the third aim, where the microendoscope will be used in situ to assess micrometastases treatment effectiveness in a mouse model of disseminated ovarian cancer for two treatment regimens. One experiment will study the effectiveness of the chemotherapy Adriamycin, while a second approach will use photodynamic therapy, where photosensitizers are used to generate cytotoxic species for tumor destruction.
PUBLIC HEALTH RELEVANCE: This project proposes the construction of a new microscopic fiber probe for the selective detection of deadly ovarian cancer metastatic tumors. By detecting these metastases, this research aims to vastly improve the detection and subsequent treatment of ovarian cancer to save the lives of women with this disease.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.pone.0023434
发表时间:
2011
期刊:
PloS one
影响因子:
3.7
作者:
[Evans CL, Abu-Yousif AO, Park YJ, Klein OJ, Celli JP, Rizvi I, Zheng X, Hasan T]
通讯作者:
Hasan T
Pharmacokinetic Tomography for the Measurement of Topical Drug Product Bioequivalence
-
批准号:10224202
-
项目类别:
-
资助金额:$24.72万
-
财政年份:2019
-
负责人:Conor Lee Evans
-
依托单位:
Pharmacokinetic Tomography for the Measurement of Topical Drug Product Bioequivalence
-
批准号:10469996
-
项目类别:
-
资助金额:$24.71万
-
财政年份:2019
-
负责人:Conor Lee Evans
-
依托单位:
Pharmacokinetic Tomography for the Measurement of Topical Drug Product Bioequivalence
-
批准号:9913677
-
项目类别:
-
资助金额:$49.94万
-
财政年份:2019
-
负责人:Conor Lee Evans
-
依托单位:
Pharmacokinetic Tomography for the Measurement of Topical Drug Product Bioequivalence
-
批准号:10686835
-
项目类别:
-
资助金额:$24.79万
-
财政年份:2019
-
负责人:Conor Lee Evans
-
依托单位:
Hyperspectral and Structural Microscopy Platform for Therapy of Resistant Cancer
-
批准号:8325052
-
项目类别:
-
资助金额:$13.25万
-
财政年份:2011
-
负责人:Conor Lee Evans
-
依托单位:
Hyperspectral and Structural Microscopy Platform for Therapy of Resistant Cancer
-
批准号:8034979
-
项目类别:
-
资助金额:$17.41万
-
财政年份:2011
-
负责人:Conor Lee Evans
-
依托单位:
Imaging and Overcoming Hypoxia-Induced Resistance in Metastatic Ovarian Cancer
-
批准号:7981069
-
项目类别:
-
资助金额:$265.5万
-
财政年份:2010
-
负责人:Conor Lee Evans
-
依托单位:
Multimodality Microendoscope for Metastatic Ovarian Cancer Detection & Treatment
-
批准号:7617802
-
项目类别:
-
资助金额:$4.72万
-
财政年份:2009
-
负责人:Conor Lee Evans
-
依托单位:
海外基金